Overview
- This week, Samsung Biologics launched an all‑cash SFr1.46bn (about $1.8bn) public tender offer to buy PolyPeptide, a Switzerland‑based contract development and manufacturing organisation that makes peptide active pharmaceutical ingredients.
- PolyPeptide operates sites in the U.S., Sweden, Belgium, France and India, reported $444 million in 2025 revenue, and guided for strong 2026 growth driven largely by metabolic drugs such as GLP‑1 therapies.
- PolyPeptide’s board has recommended shareholders accept the offer and company statements set a target to complete the deal before the end of 2026, subject to Swiss takeover rules and regulatory clearances.
- Samsung says the acquisition would expand its CDMO services beyond antibodies and ADCs into peptide therapeutics, while industry peers are also investing heavily in peptide capacity, increasing consolidation pressure in the sector.
- Analysts and former PolyPeptide staff warn that technical and organizational integration of automated solid‑phase peptide synthesis operations will determine whether the purchase delivers long‑term value for customers and workers.